zinbryta
biogen idec ltd - daclizumab - multiplā skleroze - imūnsupresanti - zinbrita ir indicēta pieaugušiem pacientiem recidivējošu multiplās sklerozes formu (rms) ārstēšanai.
docile 10 000 sv/ml pilieni iekšķīgai lietošanai, šķīdums
abiogen pharma s.p.a, italy - holekalciferols - pilieni iekšķīgai lietošanai, šķīdums - 10 000 sv/ml
docile 1000 sv cietās kapsulas
abiogen pharma s.p.a, italy - holekalciferols - kapsula, cietā - 1000 sv
docile 2000 sv cietās kapsulas
abiogen pharma s.p.a, italy - holekalciferols - kapsula, cietā - 2000 sv
docile 6000 sv cietās kapsulas
abiogen pharma s.p.a, italy - holekalciferols - kapsula, cietā - 6000 sv
docile 25 000 sv cietās kapsulas
abiogen pharma s.p.a, italy - holekalciferols - kapsula, cietā - 25 000 sv
fampyra
biogen netherlands b.v. - fampridīns - multiplā skleroze - other nervous system drugs - fampyra tiek norādīts uzlabošanas pieaugušiem pacientiem ar multiplo sklerozi iešana ar kājām invaliditātes (paplašināts invaliditātes statusa skalas 4-7).
tecfidera
biogen netherlands b.v. - dimethyl fumarate - multiplā skleroze - imūnsupresanti - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
plegridy
biogen netherlands b.v. - peginterferon beta-1a - multiplā skleroze - imunitātes stimulatori, - pieaugušiem pacientiem recidivējošas recidivējošas multiplās sklerozes ārstēšana.
tysabri
biogen netherlands b.v. - natalizumab - multiplā skleroze - selective immunosuppressants - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 un 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.